0000000000398015

AUTHOR

R. Sirna

showing 2 related works from this author

Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

2019

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and…

AdultMalemedicine.medical_specialtyHealth Knowledge Attitudes PracticeAdolescentdisease awarenessMEDLINEDermatologyDisease.030207 dermatology & venereal diseases03 medical and health sciencesDiagnostic Self EvaluationYoung Adult0302 clinical medicineHealth caremedicineEffective treatmentHumansHidradenitis suppurativa030212 general & internal medicineMass MediaYoung adultIntensive care medicineChildAdolescent; Adult; Aged; Child; Cysts; Diagnostic Self Evaluation; Female; Health Education; Health Knowledge Attitudes Practice; Hidradenitis Suppurativa; Humans; Male; Mass Media; Middle Aged; Social Media; Young Adult; CommunicationHealth EducationAgedPracticebusiness.industryCystsInflammatory skin diseaseHealth KnowledgeCommunicationhidradenitis suppurativadisease awareness communication hidradenitis suppurativaMiddle Agedmedicine.diseaseHidradenitis SuppurativaInfectious DiseasesCystAttitudesHealth educationFemalebusinessSettore MED/35 - MALATTIE CUTANEE E VENEREESocial MediaHuman
researchProduct

Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study

2021

BACKGROUND The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far. OBJECTIVES To identify clinical parameters predicting response to adalimumab and confirm its efficacy/safety. METHODS The data of 389 patients with HS treated with adalimumab in 21 Italian centres were reviewed. Sex, age at onset/diagnosis/baseline, body mass index, smoking, phenotype, previous treatments, concomitant antibiotics and 'therapeutic delay', defined as the time from HS onset to adalimumab initiation, were assessed. Response to adalimumab and its impact on quality of life (QoL) wer…

medicine.medical_specialtyVisual analogue scaleAnti-Inflammatory AgentsDermatologySeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSettore MED/35Quality of lifeInternal medicineSeverity of illnessmedicineAdalimumabHumansHidradenitis suppurativahidrosadenitis suppurativaRetrospective Studiesbusiness.industryAdalimumabRetrospective cohort studyOdds ratioDermatology Life Quality Indexmedicine.diseasehumanitiesHidradenitis SuppurativaTreatment OutcomeQuality of LifeAdalimumab Hidradenitis Suppurativa quality of lifeSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drug
researchProduct